Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 1. Abnormal expression of RPL22L1 in LUAD and its correlation with various clinical features. (A) Differential expression of RPL22L1 in pan cancer and normal tissues. (B) Specific differential expression of RPL22L1 in LUAD and normal lung tissue. (C) Differential expression of RPL22L1 in LUAD and its paired normal lung tissues. (D) The efficacy of RPL22L1 expression in distinguishing LUAD tissue from non-tumor tissue is shown by the ROC curve. (E, F) represent T stage and pathological stage, respectively. The statistical significance is represented by *, p < 0.05, * *, p < 0.01, * * *, and p < 0.001, respectively.